Y Intercept Hong Kong Ltd Has $5.84 Million Holdings in McKesson Co. (NYSE:MCK)

Y Intercept Hong Kong Ltd grew its position in shares of McKesson Co. (NYSE:MCK - Free Report) by 448.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,806 shares of the company's stock after purchasing an additional 9,654 shares during the period. Y Intercept Hong Kong Ltd's holdings in McKesson were worth $5,837,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Orion Portfolio Solutions LLC raised its position in shares of McKesson by 5.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 20,141 shares of the company's stock valued at $9,958,000 after purchasing an additional 1,108 shares in the last quarter. World Investment Advisors LLC bought a new stake in shares of McKesson in the third quarter worth $62,243,000. National Bank of Canada FI boosted its stake in McKesson by 5.4% during the 3rd quarter. National Bank of Canada FI now owns 93,432 shares of the company's stock valued at $46,194,000 after acquiring an additional 4,781 shares during the last quarter. Glen Eagle Advisors LLC grew its holdings in McKesson by 25.2% during the 3rd quarter. Glen Eagle Advisors LLC now owns 377 shares of the company's stock worth $186,000 after acquiring an additional 76 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its position in shares of McKesson by 24.7% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,258 shares of the company's stock worth $11,994,000 after purchasing an additional 4,804 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Trading Down 1.9 %

MCK stock traded down $11.68 during mid-day trading on Monday, hitting $591.85. The stock had a trading volume of 970,514 shares, compared to its average volume of 817,744. McKesson Co. has a 1-year low of $431.35 and a 1-year high of $637.51. The company has a fifty day moving average of $556.78 and a 200 day moving average of $562.15. The stock has a market capitalization of $75.13 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 1.30 and a beta of 0.49.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, beating analysts' consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. During the same quarter in the prior year, the firm posted $6.23 EPS. The firm's revenue for the quarter was up 21.3% on a year-over-year basis. As a group, sell-side analysts expect that McKesson Co. will post 32.73 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 0.48%. The ex-dividend date is Monday, December 2nd. McKesson's dividend payout ratio is currently 14.71%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MCK. Citigroup lifted their price target on shares of McKesson from $630.00 to $713.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. StockNews.com raised McKesson from a "hold" rating to a "buy" rating in a report on Wednesday, November 6th. Mizuho initiated coverage on McKesson in a report on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target on the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on McKesson from $623.00 to $579.00 and set a "buy" rating for the company in a research note on Wednesday, September 25th. Finally, Leerink Partners reduced their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $635.86.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.